This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teunissen, J. J.M. Articles by Krenning, E. P. Search for Related Content PubMed PubMed Citation Articles by Teunissen, J. J.M. Articles by Krenning, E. P. Social Bookmarking                            What's this?

Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate

From the Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

Address reprint requests to Jaap J.M. Teunissen, Department of Nuclear Medicine, Erasmus Medical Center, Dr Molenwaterplein 40, 3015 GD Rotterdam, The Netherlands; e-mail: j.teunissen{at}erasmusmc.nl

PURPOSE: To evaluate the quality of life (QoL) in patients with metastatic somatostatin receptor positive gastroenteropancreatic tumors treated with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate (¹⁷⁷Lu-octreotate) therapy.

PATIENTS AND METHODS: Fifty patients who had been treated with 600 to 800 mCi of ¹⁷⁷Lu-octreotate and had a follow-up of at least 3 months were studied. The patients completed the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 before therapy and at follow-up visit 6 weeks after the last cycle. Overall QoL and specific QoL domains of both the total group of patients and subgroups according to treatment outcome were analyzed. Twenty-four patients had regression, 19 had stable disease, six had progressive disease, and one had nonassessable disease status. Analysis of variance was used for statistical comparison.

RESULTS: A significant improvement in the global health status/QoL scale was observed after therapy with ¹⁷⁷Lu-octreotate (P < .01). The score increased significantly six weeks after therapy to a mean of 78.2, up from 69.0 (scale range, 0 to 100). Furthermore, significant improvement was observed in the role, emotional, and social function scales. The symptom scores for fatigue, insomnia, and pain were significantly decreased. Patients with proven tumor regression most frequently had an improvement of QoL domains. Unexpectedly, patients with progressive disease also indicated an improvement in their global health/QoL score.

CONCLUSION: ¹⁷⁷Lu-octreotate therapy significantly improved the global health/QoL and several function and symptom scales in patients with metastasized gastroenteropancreatic tumors, but especially in those patients with proven tumor regression.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Khanna, D. Bushnell, and M. S. O'Dorisio Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors Oncologist, April 1, 2008; 13(4): 382 - 389. [Abstract] [Full Text] [PDF]

				W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]

				H. Uusijarvi, P. Bernhardt, F. Rosch, H. R. Maecke, and E. Forssell-Aronsson Electron- and Positron-Emitting Radiolanthanides for Therapy: Aspects of Dosimetry and Production J. Nucl. Med., May 1, 2006; 47(5): 807 - 814. [Abstract] [Full Text] [PDF]

				S. H. Gunn, J. E. Schwimer, M. Cox, C. T. Anthony, M. S. O'Dorisio, and E. A. Woltering In Vitro Modeling of the Clinical Interactions Between Octreotide and 111In-Pentetreotide: Is There Evidence of Somatostatin Receptor Downregulation? J. Nucl. Med., February 1, 2006; 47(2): 354 - 359. [Abstract] [Full Text] [PDF]

				G A Kaltsas, D Papadogias, P Makras, and A B Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699. [Abstract] [Full Text] [PDF]

				F. Forrer, H. Uusijarvi, D. Storch, H. R. Maecke, and J. Mueller-Brand Treatment with 177Lu-DOTATOC of Patients with Relapse of Neuroendocrine Tumors After Treatment with 90Y-DOTATOC J. Nucl. Med., August 1, 2005; 46(8): 1310 - 1316. [Abstract] [Full Text] [PDF]

				J. M. Zuetenhorst and B. G. Taal Metastatic Carcinoid Tumors: A Clinical Review Oncologist, February 1, 2005; 10(2): 123 - 131. [Abstract] [Full Text] [PDF]